AbbVie Inc. (ABBV) announced on Monday that its Phase 3 TEMPO-2 study assessing tavapadon for early-stage Parkinson's disease successfully achieved its primary objective.
During the study, patients administered with tavapadon demonstrated a notable improvement in the combined score of Parts II and III of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), a tool utilized to evaluate the severity and progression of Parkinson's disease, compared to those who received a placebo.
The company noted it is progressing as planned to file a New Drug Application with the Food and Drug Administration (FDA) by 2025.
